Stemline Therapeutics’s Buy Rating Reaffirmed at Roth Capital (STML)
Stemline Therapeutics (NASDAQ:STML)‘s stock had its “buy” rating reaffirmed by Roth Capital in a research note issued on Friday, Analyst Ratings Network.com reports.
Shares of Stemline Therapeutics (NASDAQ:STML) opened at 12.60 on Friday. Stemline Therapeutics has a 52 week low of $12.50 and a 52 week high of $47.25. The stock has a 50-day moving average of $16.2 and a 200-day moving average of $21.65. The company’s market cap is $162.1 million.
Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.